HEALWELL Achieves Record Q3 Revenue Growth Now as a Pure-Play Global SaaS, Services & AI Company for Health Systems and Life Sciences

Rhea-AI Summary

HEALWELL (OTCQX: HWAIF) reported Q3-2025 revenue of $30.4M, a 354% increase year‑over‑year driven largely by the Orion Health acquisition. Subscription, support and maintenance revenue rose to $21.0M (+535%). The company posted positive Adjusted EBITDA of $0.7M versus a loss of $2.8M in Q3‑2024, its second consecutive quarter of positive adjusted EBITDA. IFRS net loss from continuing operations was $16.0M (up 83% YoY). HEALWELL exercised its call option to acquire the remaining 49% of Pentavere and launched AmadeusAI integrating DARWEN™. Subsequent divestments and transactions strengthened the balance sheet with approximately $9.7M in cash proceeds, positioning the company as a pure‑play AI, SaaS and services healthcare provider.

Positive

• Revenue +354% to $30.4M in Q3‑2025
• Subscription, support and maintenance revenue +535% to $21.0M
• Adjusted EBITDA positive at $0.7M (second consecutive quarter)
• Acquired remaining 49% of Pentavere on July 16, 2025
• Divestments generated approximately $9.7M cash proceeds

Negative

• IFRS net loss from continuing operations $16.0M (up 83% YoY)
• Total operating expenses rose 108% to $25.1M in Q3‑2025
• Financing expenses increased 1,032% to $3.8M in Q3‑2025

• HEALWELL achieved quarterly revenue from continuing operations of $30.4 million in Q3-2025, an increase of 354% compared to revenue of $6.7 million generated in Q3-2024. Revenue growth in the quarter was largely driven by the Orion Health acquisition.
• During Q3-2025, HEALWELL reported positive Adjusted EBITDA of $0.7 million, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024. This marks the Company's second consecutive quarter of positive Adjusted EBITDA, highlighting continued execution improvements and stronger financial performance. During Q3-2025, the Company's IFRS net loss from continuing operations was $16.0 million compared to a net loss of $8.7 million for the previous year.
• During Q3-2025, HEALWELL acquired the remaining 49% interest in Pentavere Research Group Inc., gaining full ownership of the AI company and strengthening its AI segment with Pentavere's DARWEN™ platform for early disease detection.
• Subsequent to the end of the quarter, HEALWELL completed a series of strategic divestments, including the sale of its Polyclinic Family Medicine and Specialty Clinics, the sale of its majority interest in Mutuo Health Solutions, and the formation of a 50/50 clinical research joint venture with WELL Health Technologies Corp.

Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce its unaudited interim condensed consolidated financial results for the quarter ended September 30, 2025. A summary of the Company's financial and operational results is set out below, and more detailed information is contained in the interim financial statements and related management discussion and analysis, which are available on the Company's SEDAR+ page at www.sedarplus.com. Financial measures described as "Adjusted" in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies. Please see Non-IFRS Financial Measures below for more information.

James Lee, Chief Executive Officer of HEALWELL, commented, "We are pleased to report HEALWELL's second consecutive quarter of positive Adjusted EBITDA, underscoring the strong execution of our growth strategy and the improving financial performance of our business. Building on this momentum, our recent strategic divestments - including the sale of Polyclinic Family Medicine and Specialty Clinics to WELL Health Clinic Network, the sale of our majority interest in Mutuo Health Solutions, and the formation of a 50/50 clinical research joint venture WELL Research LP - allow us to sharpen our focus on becoming a pure-play AI and SaaS healthcare company. These steps strengthen our balance sheet, accelerate the commercialization of our AI solutions, and give us more time and resources to further develop our AI and healthcare software, delivering advanced preventative care technologies to health systems globally."

James Lee added, "Furthermore, we are excited by the momentum HEALWELL is building on the global stage. Our recent week of business development and investor engagement in the UK showcased the growing recognition of our AI-driven preventative healthcare solutions, while our strategic collaboration with Lean and Orion Health in the Middle East positions us to co-develop and deploy next-generation AI solutions across one of the world's most dynamic healthcare markets. Together, these initiatives demonstrate HEALWELL's expanding international presence, our ability to collaborate with leading partners, and the exciting opportunities ahead as we continue shaping the future of AI-powered healthcare. I am truly excited for how HEALWELL is shaping and what the future holds for the company."

Anthony Lam, Chief Financial Officer of HEALWELL, commented, "Our Q3 results demonstrate continued financial strength and operational progress. Revenue from continuing operations grew 354% year-over-year, reflecting the contribution of Orion Health and other strategic initiatives. The AI segment continues to perform strongly, with revenues increasing approximately 79% year-over-year. We closed the quarter with $15.6 million in cash, and recent divestments added an additional $9.4 million, further strengthening our balance sheet. These financial resources position us to accelerate the commercialization of our AI and healthcare software solutions, invest in growth, and continue delivering value to shareholders while executing on our strategy as a pure-play AI SaaS healthcare company."

Third Quarter 2025 Financial Highlights

Significant financial highlights for the Company's continuing operations during the three months ended September 30, 2025 included:

• HEALWELL achieved quarterly revenue from continuing operations of $30.4 million in Q3-2025, an increase of 354% compared to revenue of $6.7 million generated in Q3-2024. The acquisition and integration of Orion Health, along with both organic and inorganic initiatives, contributed significantly to overall revenue growth.
• HEALWELL achieved Gross Profit of $16.5 million during Q3-2025, an increase of 330% compared to $3.8 million in Q3-2024. The increase is due higher revenues in the quarter.
• HEALWELL achieved Gross Margin percentage of 54% during Q3-2025, compared to 57% in Q3-2024.
• During Q3-2025, HEALWELL reported positive Adjusted EBITDA of $0.7 million, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024. This marks the Company's second consecutive quarter of positive Adjusted EBITDA, highlighting continued execution improvements and stronger financial performance, representing a year-over-year increase of approximately 125% in Adjusted EBITDA.
• During Q3-2025, the Company's IFRS net loss from continuing operations was $16.0 million compared to a net loss of $8.7 million for the previous year.
• As of September 30, 2025, HEALWELL had $15.6 million in cash, compared to $9.4 million as of December 31, 2024.

Third Quarter 2025 Business and Operational Highlights

Significant business and operational highlights for the Company during the three months ended September 30, 2025 included:

• Full Ownership of Pentavere and Strong AI Segment Performance: On July 16, 2025, HEALWELL announced that it had exercised its call option to acquire the remaining 49% interest in Pentavere Research Group Inc., gaining full ownership of the award-winning and globally recognized AI healthcare company. Pentavere is the developer of DARWEN™, a leading AI-driven patient identification platform that enables early disease detection and supports preventative care initiatives. With 100% ownership, HEALWELL is deepening the integration of Pentavere within its AI business segment, alongside Khure Health, to accelerate commercialization of its AI technologies across the healthcare ecosystem.
• Intrahealth Selected by Public Health Sudbury to Implement Advanced EMR Platform: On September 18, 2025, HEALWELL announced that its subsidiary, Intrahealth Systems Limited, was selected by Public Health Sudbury & Districts to implement Profile, its enterprise-grade electronic medical record (EMR) platform. This strategic deployment will modernize digital infrastructure across the Sudbury and Manitoulin districts, equipping public health with advanced tools to support infectious disease control, vaccination, oral health, family health, sexual health, and environmental health programs.
• Global Launch of AmadeusAI and Integration of HEALWELL's DARWEN™ AI: On September 25, 2025, HEALWELL announced the global launch of Amadeus AI, its next-generation AI-enabled digital care record built on Orion Health's Amadeus platform. The new platform deeply integrates HEALWELL's DARWEN™ AI technology, providing healthcare providers with advanced capabilities to analyze both structured and unstructured clinical data, identify at-risk patients, and deliver proactive care. Amadeus AI introduces HEALWELL's SMARTSuite of AI tools - SMARTSearch, SMARTSummary, and SMARTIdentify - which streamline information retrieval, synthesize patient data, and enable early disease detection and intervention.

Events Subsequent to September 30, 2025

Significant business and operational highlights for the Company subsequent to September 30, 2025 included:

• DARWEN™ AI Generates Regulatory-Grade Real-World Data in Collaboration with a major pharmaceutical firm: On October 6, 2025, HEALWELL, in collaboration with a major pharmaceutical firm, presented new AI-generated regulatory-grade real-world data (RWD) at United European Gastroenterology (UEG) Week in Berlin. This represents one of the world's first applications of AI to generate regulatory-grade RWD for pharmaceutical use, highlighting HEALWELL's unique capabilities in clinical data abstraction and real-world evidence generation. DARWEN™'s ability to extract actionable insights from structured and unstructured clinical data positions HEALWELL to drive both clinical and commercial value while advancing patient-centered care globally.
• UK Business Development and Investor Awareness Week: In the week of October 14, 2025, HEALWELL completed a week-long series of business development and investor awareness activities in the United Kingdom, engaging with prospective investors, strategic partners, and potential acquisition targets. The visit included an invitation-only event in London on October 14, 2025, attended by healthcare leaders, institutional investors, and financial institutions, featuring a fireside chat moderated by Beatrice York, founder of BY-EQ Limited. The discussions highlighted the growth potential of HEALWELL's AI-driven preventative healthcare solutions, underscored the Company's longstanding role as a key data science vendor for the UK National Health Service (NHS), and reinforced opportunities to leverage the Orion Health acquisition to expand its international footprint.
• Strategic Collaboration with Lean and Orion Health to Advance AI-Powered Healthcare Across the Middle East: On October 28, 2025, HEALWELL announced a collaboration with Lean Business Services ("Lean"), a Public Investment Fund (PIF)-backed Saudi digital health leader, and its subsidiary Orion Health to co-develop and commercialize digital health and AI-driven solutions across the Middle East. The partnership builds on Orion Health's deployment of Saudi Arabia's national health information exchange (nphies) and combines Lean's market leadership with HEALWELL's advanced AI capabilities to enhance population health and interoperability.
• Strategic Divestments and Progression to a Pure-Play SaaS and Services Business: On November 3, 2025, HEALWELL announced the completion of a series of strategic transactions with WELL Health Technologies Corp. and its subsidiaries to streamline operations and sharpen its focus on AI-driven healthcare solutions. HEALWELL divested its Polyclinic Family Medicine and Specialty Clinics (two clinics) to WELL Health Clinic Network Inc., formed a 50/50 clinical research joint venture named WELL Research LP with WELL Health Technologies Corp. combining Bio Pharma Services Inc. and Canadian Phase Onward Inc., and sold its majority interest in Mutuo Health Solutions Inc. to WELLSTAR Technologies Corp. Collectively, these transactions strengthened HEALWELL's balance sheet with approximately $9.7 million in cash proceeds and mark a key step in its transition to a pure-play AI SaaS and services company focused on delivering enterprise-grade data science and preventative care technologies.?

Webcast and Conference Call Details:

HEALWELL will be holding a conference call and simultaneous webcast to discuss its financial results on Friday, November 7, 2025 at 8:30 am ET (5:30 am PT). The call will be hosted by James Lee, Chief Executive Officer, Dr. Alexander Dobranowski, President, and Anthony Lam, Chief Financial Officer. Please dial-in 10 minutes prior to the start of the call.

Date: Friday, November 7, 2025
Time: 8:30 AM ET / 5:30 AM PT
Webcast link: https://www.gowebcasting.com/14389
Toll-Free North America: 1 (800) 715-9871
International Toll: 1 (647) 932-3411

When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to be joined into the "HEALWELL AI Inc. Conference Call."

Selected Financial Information
(in thousands of dollars, except percentages and per share amounts)

	Three months ended September 30,		Period -Over-Period  Change			Nine months ended September 30,		Period -Over-Period  Change
	2025	2024	$	%		2025	2024	$	%
Revenue	30,354	6,688	23,666	354%		71,587	12,918	58,669	454%
Cost of Sales	13,844	2,850	10,994	386%		31,940	5,801	26,139	451%
Gross Profit	16,510	3,838	12,672	330%		39,647	7,117	32,530	457%
Operating Expenses
General and administrative	8,187	5,539	2,648	48%		23,049	14,088	8,961	64%
Research and development	4,892	1,090	3,802	349%		12,121	2,946	9,175	311%
Sales and marketing	2,386	556	1,830	329%		5,822	1,224	4,598	376%
Stock compensation	3,148	3,237	(89)	-3%		10,169	4,420	5,749	130%
Amortization of intangible assets	5,565	1,530	4,035	264%		12,863	4,194	8,669	207%
Depreciation of property equipment	192	68	124	182%		465	204	261	128%
Depreciation of ROU assets	732	64	668	1044%		1,276	186	1,090	586%
Impairment charges	-	-	-	0%		-	850	(850)	-100%
Total Operating Expenses	25,103	12,085	13,018	108%		65,765	28,112	37,653	134%
Income from Operations	(8,593)	(8,247)	(346)	4%		(26,118)	(20,995)	(5,123)	24%
Other Income and Expenses
Financing expenses	3,769	333	3,436	1032%		6,750	1,451	5,299	365%
Effect of foreign exchange rate	1,927	-	1,927	0%		644	-	644	0%
Changes in FMV of Contingent Consideration, Investments and Options	1,116	400	716	179%		2,757	1,050	1,707	163%
Changes in FV of derivative liability	488	-	488	0%		(2,838)	-	(2,838)	0%
Loss on fixed assets write off	-	-	-	0%		-	228	(228)	-100%
Debt forgiveness	-	-	-	0%		-	(7,863)	7,863	-100%
Liability extinguishment	-	-	-	0%		-	(3,088)	3,088	-100%
Current and Deferred Taxes	106	(245)	351	-143%		(1,062)	(1,228)	166	-14%
Net loss from continuing operations	(15,998)	(8,735)	(7,263)	83%		(32,369)	(11,545	(20,824)	180%
Net loss from discontinued operations	(12,011)	(2,385)	(9,626)	-404%		(13,803)	(2,267)	(11,536)	509%
Net loss for the period	(28,009)	(11,120)	(16,889)	-152%		(46,172)	(13,812	(32,360)	234%
EBIDTA1	(6,366)	(7,048)	682	10%		(13,353)	(6,924)	(6,429)	93%
ADJUSTED EBIDTA1	713	(2,834)	3,546	125%		892	(10,524	11,416	108%
Subscription, Support and  Maintenance Revenue	21,014	3,310	17,704	535%		45,699	7,318	38,381	524%

 

Non-IFRS Financial Measures

The terms EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin used in this document do not have any standardized meaning under IFRS, may not be comparable to similar financial measures disclosed by other companies and should not be considered a substitute for, or superior to, IFRS financial measures. Readers are advised to review the section entitled "Non-IFRS Financial Measures" in the Company's management discussion and analysis for the quarter ended September 30, 2025, available on the Company's SEDAR+ page at www.sedarplus.com, for a detailed explanation of the composition of these measures and their uses.

The following table reconciles EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin to net income (loss) for the three-months and nine months ended September 30, 2025 and September 30, 2024:

	Three months ended		Nine months ended
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
	$	$	$	$
Net Income (loss)	(15,998)	(8,735)	(32,369)	(11,545)
Add: Financing expenses	3,769	333	6,750	1,451
Add: Depreciation of property equipment	192	68	465	204
Add: Amortization of intangible assets	5,565	1,530	12,863	4,194
Add: Current and deferred taxes	106	(245)	(1,062)	(1,228)
Add: Restructuring and Integration cost	54	-	532	-
Add: Effect of foreign exchange rate	1,927	-	644	-
Add: Changes in FMV of Contingent Consideration, Investments Options	1,115	400	2,757	1,050
Add: Stock compensation	3,148	3,237	10,169	4,420
Add: Acquisition related expenses	347	514	2,981	1,467
Less: Changes in FV of derivative liability	488	-	(2,838)	-
Add: Impairment charges	-	64	-	186
Add: Loss on fixed assets write off, Debt Forgiveness, and Liability Extinguishment	-	-	-	(10,723)
Adjusted EBITDA	713	(2,834)	892	(10,524)

 

Segmented Revenue

	Three months ended  September 30,		Period -Over- Period Change			Nine months ended  September 30,		Period -Over- Period Change
	2025	2024	$	%		2025	2024	$	%
Healthcare Software	28,381	5,586	22,795	408%		64,532	10,241	54,291	530%
AI and Data sciences	1,973	1,102	871	79%		7,055	2,677	4,378	164%
Total	30,354	6,688	23,666	354%		71,587	12,918	58,669	454%

 

James Lee
Chief Executive Officer
HEALWELL AI Inc.

About HEALWELL

HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.

Forward-Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and its partners to continually leverage advancements in expert AI technologies to develop new products and services or enhance existing ones; the anticipated impact of the recent divestment of HEALWELL's clinical research and patient services businesses; and discussions with potential collaborators, investors and acquisition targets ; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "strengthening", "growth", "strategy", "accelerate", "further develop", "growing", "positions", "expanding", "opportunities", "future", "is deepening", "prospective", "potential", "transition"

or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability toleverage Orion Health personnel, products, services, customers and relationships; HEALWELL's ability to maintain and leverage is relationships with its commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships; H the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

For more information:

Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273420

FAQ

What were HEALWELL (HWAIF) Q3‑2025 total revenues and growth rate?

HEALWELL reported $30.4M in Q3‑2025 revenue, a 354% increase year‑over‑year.

How did HEALWELL's Adjusted EBITDA perform in Q3‑2025 for HWAIF?

Adjusted EBITDA was $0.7M in Q3‑2025, versus a loss of $2.8M in Q3‑2024.

What acquisition did HEALWELL complete in July 2025 affecting HWAIF?

On July 16, 2025 HEALWELL exercised a call option to acquire the remaining 49% of Pentavere, gaining full ownership.

How much cash did HEALWELL hold at September 30, 2025 and from divestments?

HEALWELL closed Q3 with $15.6M in cash and subsequent divestments added approximately $9.7M.

What drove HEALWELL's subscription revenue growth in Q3‑2025 (HWAIF)?

Subscription, support and maintenance revenue rose to $21.0M, up 535%, driven by Orion Health integration and recurring SaaS contracts.

Did HEALWELL launch any new products or platforms in Q3‑2025 for HWAIF?

Yes — HEALWELL launched AmadeusAI on September 25, 2025, integrating DARWEN™ AI and SMARTSuite tools.

What is the main near‑term financial risk highlighted by HEALWELL's Q3‑2025 results (HWAIF)?

Despite revenue gains, the company reported an IFRS net loss from continuing operations of $16.0M and materially higher operating and financing expenses.